Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,701–6,800 of 15,747
Cazzato, G., Romita, P., Foti, C., Cimmino, A., Colagrande, A., Arezzo, F., Sablone, S., Barile, A., Lettini, T., Resta, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9070760 · Cited by 11
mRNA vaccines: hope beneath the hype
Extance, A. (2021) · BMJ · doi:10.1136/bmj.n2744 · Cited by 11
Azzolini, E., Canziani, L. M., Voza, A., Desai, A., Pepys, J., Santis, M. D., Ceribelli, A., Pozzi, C., Turato, M., Badalamenti, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10030439 · Cited by 11
“Effective vaccines are essential to limit the viral spread, and the Pfizer–BioNTech BNT162b2 vaccine based on a nucleoside-modified mRNA [1] was the first to be approved by both European and United States regulatory agencies [2] among the four currently approved vaccines [3,4].”
BackgroundResultKim, M., Kang, G., Min, H. S., Lee, Y., Park, S., & Jung, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2422939 · Cited by 11
“The critical role of vaccination has become even more apparent during the COVID-19 pandemic, which emerged in 2019 and posed a formidable challenge to global health systems [13].”
Time and cost of administering COVID-19 mRNA vaccines in the United States
Yarnoff, B., Bodhaine, S., Cohen, E., & Buck, P. O. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1974289 · Cited by 10
“After genomic sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, messenger RNA (mRNA)based vaccines were developed by Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2).(2,3) In December 2020, both vaccines were authorized by the US Food and Drug Administra…”
BackgroundAdenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics
Farhad, T., Neves, K., Arbuthnot, P. B., & Maepa, M. B. (2022) · Genes · doi:10.3390/genes13111941 · Cited by 11
“Nucleic-acid-based vaccines induce a more durable and broader immune response, with mRNA vaccines generally inducing the highest overall protective efficacy [17,19,20].”
BackgroundZarei, M., Rahimi, K., Hassanzadeh, K., Abdi, M., Hosseini, V., Fathi, A., & Kakaei, K. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111555 · Cited by 12
Implication of mass COVID‐19 vaccination on dermatology practice in 2021
Sinha, A., Kumar, R., & Singh, A. R. (2021) · Dermatologic Therapy · doi:10.1111/dth.14765 · Cited by 12
Yoshifuji, A., Toda, M., Ryuzaki, M., Oyama, E., Kikuchi, K., Kawai, T., Sakai, K., Koinuma, M., Katayama, K., Yokoyama, T., et al. (2023) · Vaccines · doi:10.3390/vaccines11030653 · Cited by 12
“The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had devastating effects on healthcare, the economy, and society since 2020 [1].”
BackgroundCOVID ‐19 in cancer patients: The impact of vaccination on outcomes early in the pandemic
Khawaja, F., Angelidakis, G., Feldman, A., Ravi, V., Woodman, E. B., Bhatti, M. M., Ariza‐Heredia, E., Elhajj, P., Spallone, A., Jiang, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6781 · Cited by 12
“3,4 36 Multiple factors may explain this discrepancy, such as the rise of the new delta variant and other variants of concern 22,35,37 during that time; increased infection rate among vaccinated elderly, immunocompromised, and cancer patients 33,35,36 ; and waning immunity from the COVID-19…”
BackgroundTolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals
Zdanowski, W., Markiewicz, A., Zdanowska, N., Lipińska, J., & Waśniewski, T. (2022) · Vaccines · doi:10.3390/vaccines10020200 · Cited by 10
Obel, N., Fox, M. P., Tetens, M. M., Pedersen, L. H., Krause, T. G., Ullum, H., & Sørensen, H. T. (2024) · Clinical Epidemiology · doi:10.2147/clep.s468572 · Cited by 13
Mochizuki, T., Hori, T., Yano, K., Ikari, K., & Okazaki, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8902-21 · Cited by 11
“The BNT162b2 vaccine was 95% effective in preventing COVID-19 occurrence (1).”
BackgroundTayyar, Y., Idris, A., & Yassine, H. M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s517385 · Cited by 17
Nanoparticle-hydrogel composites for precision medicine
Parveen, S., Bozal, S. B., Pober, J. S., & Saltzman, W. M. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100372 · Cited by 22
Hagiya, H., Nakano, Y., Furukawa, M., Sunada, N., Hasegawa, T., Sakurada, Y., Hasegawa, K., Yamamoto, K., Ogawa, H., Obara, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24464-3 · Cited by 13
Engebretsen, S., Rø, G., & de Blasio, B. F. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01565-1 · Cited by 13
Seong, G. M., Baek, A.-R., Baek, M. S., Kim, W., Kim, J. H., Lee, B. Y., Na, Y. S., & Lee, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121258 · Cited by 11
Central Nervous System Effects of COVID-19 in People with HIV Infection
Peluso, M. J., Hellmuth, J. M., & Chow, F. C. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00582-x · Cited by 11
Alves, K., Kotloff, K. L., McClelland, R. S., Kouassi, A., Plested, J. S., Kalkeri, R., Zhu, M., Cloney-Clark, S., Cai, Z., Smith, K. C., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00670-4 · Cited by 16
Zou, C., Xue, X., & Qian, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.826327 · Cited by 14
Teeyapun, N., Luangdilok, S., Pakvisal, N., Sainamthip, P., Mingmalairak, S., Poovorawan, N., Sitthideatphaiboon, P., Parinyanitikul, N., Sriuranpong, V., Namkanisorn, T., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101608 · Cited by 11
Talukder, A., Kalita, C., Neog, N., Goswami, C., Sarma, M. K., & Hazarika, I. (2022) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2021-0301 · Cited by 12
“It is a vaccine for preventing coronavirus disease 2019 (COVID-19) in individuals aged 16 years and older [31].”
BackgroundPernio‐like skin lesions after the second dose of Pfizer‐BioNTech COVID‐19 vaccine
Cameli, N., Silvestri, M., Mariano, M., Nisticò, S. P., & Cristaudo, A. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17500 · Cited by 11
Lawal, B., Kuo, Y.-C., Sumitra, M. R., Wu, A. T. H., & Huang, H. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105814 · Cited by 13
Návar, A. M., McNally, E. M., Yancy, C. W., O’Gara, P. T., & Bonow, R. O. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2853 · Cited by 12
Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review
Rahmig, J., Altarsha, E., Siepmann, T., & Barlinn, K. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s374549 · Cited by 16
“Messenger RNA vaccines are using non-virulent coding SARS-CoV-2 mRNA, coated with lipid particles.(6,7) This vaccination induces the synthesis of SARS-CoV-2 proteins through translation of mRNA in the cytoplasm.”
BackgroundMethodWang, S., Cui, H. Y., Zhang, C., Li, W., Wang, W., He, W., Feng, N., Zhao, Y., Wang, T., Tang, X., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105765 · Cited by 11
Gröschel, J., Bhoyroo, Y., Błaszczyk, E., Trauzeddel, R. F., Viezzer, D., Saad, H., Fenski, M., & Schulz‐Menger, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.916922 · Cited by 15
“Along with the development of messenger RNA-based vaccines targeting the COVID-19 virus, reports on postvaccination myocarditis followed (17, 18).”
BackgroundKatoto, P. D., Tamuzi, J. L., Brand, A., Marangu, D., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2214495 · Cited by 14
“(10) Booster; Omicron variant; 12-15 years old Overall VE and BNT162b2 in adolescents”
BackgroundInfluentialHeterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination
Graninger, M., Camp, J. V., Aberle, S. W., Traugott, M. T., Hoepler, W., Puchhammer‐Stöckl, E., Weseslindtner, L., Zoufaly, A., Aberle, J. H., & Stiasny, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888794 · Cited by 12
“24 (100) 13 (43) Median age in years [range] 37 [19-89] 25 [20-35] 51 [19-89] 45 [20-58] Male sex (%) 43 (49) 15 (63) 23 (77) 5 (15) “Early” samples in dpo/dpv [range] 19 [9-41] 25 [14-41] 18 [9-25] 17 [10-28] “Late” samples in dpo/dpv [range] 176 [107-429] 184 [170-219] 235 [169-429] 162 [107-183] Sequenced (% of N)…”
Hara, S., Arase, S., Sano, S., Suzuki, T., Mizogaki, I., Sato, S., & Ukai, K. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124317 · Cited by 13
Otter, A. D., D’Arcangelo, S., Whitaker, H., Hewson, J., Foulkes, S., Atti, A., Cole, M. J., Linley, E., Tonge, S., Hettiarachchi, N., et al. (2022) · medRxiv · doi:10.1101/2022.04.21.22274025 · Cited by 11
Nanomedicines modulate the tumor immune microenvironment for cancer therapy
Chao, P., Chan, V., & Li, S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2412245 · Cited by 13
“The success of COVID-19 vaccines utilizing mRNA-loaded lipid nanoparticles (LNPs) in providing effective immunization against the SARS-CoV-2 virus has been recognized globally, showcasing tremendous potential of this technology for human health [48,49].”
Murthy, S. K., Kuenzig, M. E., Windsor, J. W., Ghia, J., Griffiths, A. M., Panaccione, R., Seow, C. H., Benchimol, E. I., Bernstein, C. N., Bitton, A., et al. (2021) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwab033 · Cited by 13
COVID-19: Vaccines and therapeutics
Swapna, P., Birudukota, N. V. S., & Kamal, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128987 · Cited by 15
Mislang, A. R., Soto‐Pérez‐de‐Celis, E., Russo, C., Colloca, G. A., Williams, G. R., O’Hanlon, S., Cooper, L., O’Donovan, A., Audisio, R. A., Cheung, K., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.03.003 · Cited by 12
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
Asdaq, S. M. B., Jomah, S., Rabbani, S. I., Alamri, A. M., Alshammari, S. K. S., Duwaidi, B. S., Al-Shammari, M., Alamri, A. S., Alsanie, W. F., Alhomrani, M., et al. (2022) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2022/6913772 · Cited by 13
“Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine [19] Phase 3, doubleblind, randomized, controlled trial Two doses of either 30 mcg of vaccine or placebo with 21 days apart were given and followed up for two months to 43,548 participants (≥16 years, healthy.”
BackgroundResultInfluentialKim, D., Lee, S. J., Park, S., Kim, P., Lee, S. M., Lee, S. M., Shum, D., Kim, D. H., & Kim, E. H. (2022) · Vaccines · doi:10.3390/vaccines10111864 · Cited by 11
“4%) with potent humoral immune responses to the original SARS-CoV-2 strain and decent levels of T-cell responses [3,4].”
BackgroundVasileiou, E., Shi, T., Kerr, S., Robertson, C., Joy, M., Tsang, R. S. M., McGagh, D., Williams, J., Hobbs, R. F., de Lusignan, S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-050062 · Cited by 11
Construction and immunogenicity of an mRNA vaccine against chikungunya virus
Liu, J., Lu, X., Li, X., Huang, W., Fang, E., Li, W., Liu, X., Liu, M., Li, J., Li, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129118 · Cited by 11
Watkins, L. F., Mitruka, K., Dorough, L., Bressler, S. S., Kugeler, K. J., Sadigh, K. S., Birhane, M. G., Nolen, L. D., & Fischer, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac066 · Cited by 11
“Clinical trials involving at least 76,000 participants demonstrated these vaccines to be safe and highly efficacious in preventing symptomatic COVID-19 and subsequent observational studies confirmed these findings.[2-9] Real-world data provided further evidence that these vaccines are highly effective in preventing ho…”
BackgroundAlali, W. Q., Ali, L. A., AlSeaidan, M., & Al-Rashidi, M. (2021) · Healthcare · doi:10.3390/healthcare9121692 · Cited by 13
“These findings are consistent with those from other population-level studies that estimated vaccine effectiveness against SARS-CoV-2 infection (symptomatic and/or asymptomatic) among HCWs [4,7,8,11] and those from vaccine phase III trials [2,18].”
ResultShort-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
Paran, Y., Saiag, E., Spitzer, A., Angel, Y., Yakubovsky, M., Padova, H., Ben‐Ami, R., Goldinger, I., Gamzu, R., Sprecher, E., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab656 · Cited by 12
“DISCUSSION In this observational study of immunocompetent HCWs who received a third (booster) vaccine dose BNT162b2, the local and systemic reactions within 1 week after vaccination were mild and were similar to those observed in previous studies that evaluated the safety of the BNT162b2 primary series [1, 7].”
Jaber, A., Patel, M. H., Sylvester, A., Yarussi, M., Kalina, J. T., Mendoza, J. P., Avila, R. L., & Tremblay, M. A. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00448-x · Cited by 13
“As such, both mRNA vaccines encode epitopes of the spike glycoprotein as the target immunogen [5, 6].”
BackgroundYang, D., Lin, F.-C., Tsai, P.-H., Chien, Y., Wang, M., Yang, Y., & Chang, T.-J. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000542 · Cited by 11
Buehrle, D. J., Sutton, R. R., McCann, E. L., & LUCAS, A. E. (2021) · Viruses · doi:10.3390/v13091706 · Cited by 12
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-309746/v1 · Cited by 17
Alsulaiman, J., Alzoubi, A., Alrawashdeh, A., Al-Dekah, A. M., Abubaker, S., Amayreh, W., Sweileh, W. M., Alzoubi, H. M., & Kheirallah, K. A. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.102597 · Cited by 10
Voulgaridi, I., Sarrou, S., Dadouli, K., Peristeri, A.-M., Nasika, A., Onoufriadis, I., Kyritsi, M. A., Anagnostopoulos, L., Theodoridou, A., Avakian, I., et al. (2022) · Vaccines · doi:10.3390/vaccines10081268 · Cited by 11
BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease
Rossi, C., Lanuti, P., Cicalini, I., Bellis, D. D., Pierdomenico, L., Boccio, P. D., Zucchelli, M., Natale, L., Sinjari, B., Catitti, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9101164 · Cited by 12
Acute Mild Pancreatitis Following COVID-19 mRNA Vaccine in an Adolescent
Kantar, A., Seminara, M., Odoni, M., & Verde, I. D. (2021) · Children · doi:10.3390/children9010029 · Cited by 11
“Among the most frequently reported gastrointestinal side effects are nausea, diarrhoea, decreased appetite, abdominal pain, vomiting, heartburn, and constipation [7].”
BackgroundNatalini, A., Simonetti, S., Sher, C., D’Oro, U., Hayday, A., & Rosa, F. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214367 · Cited by 15
“By contrast, serum-neutralizing antibodies were barely detectable at these early time points post-priming, and yet effective protection was already achieved [7,51].”
Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism
Jakwerth, C. A., Feuerherd, M., Guerth, F. M., Oelsner, M., Schellhammer, L., Giglberger, J., Pechtold, L., Jerin, C., Kugler, L. M., Mogler, C., et al. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02182-7 · Cited by 13
“SARS-CoV-2 vaccines have been approved worldwide since the end of 2020 and are starting to show their protective effects in public health [1, 2].”
BackgroundPosicionamiento de la Sociedad Española de Nefrología ante la vacunación frente al SARS-CoV-2
Sánchez-Álvarez, E., Quiroga, B., & de Sequera, P. (2021) · Nefrología · doi:10.1016/j.nefro.2020.12.002 · Cited by 12
Bredholt, G., Sævik, M., Søyland, H., Ueland, T., Zhou, F., Pathirana, R. D., Madsen, A., Vahokoski, J., Lartey, S. L., Halvorsen, B. L., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100564 · Cited by 14
“The primary vaccination schedule consists of two doses administered 21 days apart [1], but subsequent studies have indicated that extending the interval between doses can enhance the immunogenicity of this vaccine [2,3].”
BackgroundCostiniuk, C. T., Singer, J., Langlois, M., Kulić, I., Needham, J., Burchell, A. N., Jenabian, M.-A., Walmsley, S. L., Ostrowski, M., Kovacs, C. M., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-054208 · Cited by 12
Rayner, D. G., Nunes, J. T., Gou, D., Chu, A. W. L., Dai, S.-C., Sheikh, A., Meng, D., Orchanian‐Cheff, A., Oss, S., Rotstein, C., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.07.031 · Cited by 12
Cegolon, L., Mastrangelo, G., Bellizzi, S., Filon, F. L., & Salata, C. (2023) · Pathogens · doi:10.3390/pathogens12020211 · Cited by 12
Dynamics of the COVID-19 epidemic in the post-vaccination period in Korea: a rapid assessment
Min, K., & Tak, S. (2021) · Epidemiology and Health · doi:10.4178/epih.e2021040 · Cited by 11
“Assumptions regarding the effectiveness of the vaccines were obtained from published papers [10-13].”
BackgroundChinazzi, M., Davis, J. T., y Piontti, A. P., Mu, K., Gozzi, N., Ajelli, M., Perra, N., & Vespignani, A. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100757 · Cited by 13
“It is important to note that during the scenario design phase, detailed information on vaccine efficacy was limited, except for the efficacy against symptomatic disease, which was informed by phase 3 trials (Polack et al., 2020; Pilishvili et al., 2021).”
BackgroundSentinel cells enable genetic detection of SARS-CoV-2 Spike proteinPreprint
Weinberg, Z. Y., Hilburger, C. E., Kim, M. J., Cao, L., Khalid, M. M., Elmes, S., Diwanji, D. C., Hernandez, E., Lopez, J., Schaefer, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440678 · Cited by 12
“At the forefront, multiple vaccines 17,18 have been developed based on the decades-old prom‐ ise of mRNA therapeutics 19 .”
Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination
Tanaka, H., Nagasato, D., Nakakura, S., Nagasawa, T., Wakuda, H., Kurusu, A., Mitamura, Y., & Tabuchi, H. (2022) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_24_22 · Cited by 11
“[2] Since its initial outbreak, SARS‐CoV‐2 has been rapidly spreading, therefore, to limit its further spread, vaccination campaigns have been ongoing worldwide.[3] Some of the most commonly reported postvaccination mild reactions include pain, redness, swelling around the injection site, fever, headache, myalgia, and…”
BackgroundDon’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
Morris, V. K., & Kopetz, S. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00463-4 · Cited by 12
Aznar-Gimeno, R., Paño‐Pardo, J. R., Esteban, L. M., Labata-Lezaun, G., Esquillor-Rodrigo, M. J., Lanas, Á., Abadía, D., Díez‐Fuertes, F., Tellería, C., Alonso, R. D. H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98308-x · Cited by 10
Baek, Y. J., Kim, W., Ko, J., Lee, Y.-J., Ahn, J. Y., Kim, J. H., Jang, H. C., Jeong, H. W., Kim, Y. C., Park, Y. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.063 · Cited by 12
“Two doses of BNT162b2 had 95 % (95 % confidence interval [CI], 90– 98 %) efficacy against symptomatic COVID-19 [2], and two doses of AZD1222 had 70 % (95 % CI, 55–81 %) efficacy [3].”
BackgroundSafety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
Leal, L., Pich, J., Ferrer, L., Nava, J., Martí‐Lluch, R., Esteban, I., Pradenas, E., Regué, D. R., Prenafeta, A., Escobar, K., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00736-5 · Cited by 15
Emerging infectious diseases, vaccines and Guillain–Barré syndrome
Koike, H., & Katsuno, M. (2021) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12644 · Cited by 13
Alhuzaimi, A., Alrasheed, A. A., Al-Eyadhy, A. A., Aljamaan, F., Alhasan, K. A., Batais, M. A., Jamal, A. A., Alshahrani, F. S., Alenezi, S., Alhaboob, A. A. N., et al. (2023) · Healthcare · doi:10.3390/healthcare11070972 · Cited by 12
“Results of an ongoing phase 1–2–3 clinical study in healthy persons 12 years of age or older support the safety, immunogenicity, and efficacy of a two-dose series of 30 μg BNT162b2 injections administered 21 days apart [1,8].”
BackgroundGonzalez‐Garcia, P., Muñoz-Miranda, J. P., Fernández-Cisnal, R., Olvera-Collantes, L., Moares, N., Gabucio, A., Fernandez-Ponce, C. M., & Garcia-Cozar, F. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087641 · Cited by 12
Mwimanzi, F., Lapointe, H., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., et al. (2022) · medRxiv · doi:10.1101/2022.01.06.22268745 · Cited by 24
del Cura-Bilbao, A., López-Mendoza, H., Chaure-Pardos, A., Ugarriza, A. V., & Guimbao-Bescós, J. (2022) · Emerging infectious diseases · doi:10.3201/eid2803.212027 · Cited by 12
Cai, G., Liu, S., Lu, Y., Takaki, Y., Matsumoto, F., Yoshikawa, A., Taguri, T., Xie, J., Arima, K., Mizukami, S., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2322795 · Cited by 13
“11,12 13–15 Moreover, vaccination significantly reduced the risk of hospitalization or COVID-19 related mortality and resulted in a shorter recovery period for non-hospitalized patients.”
BackgroundLipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy
Alshehry, Y., Liu, X., Li, W., Wang, Q., Cole, J., & Zhu, G. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01051-8 · Cited by 19
“Among these delivery systems, lipid-based nanocarriers, especially LNPs, have shown great potential for mRNA delivery thus far (29, 30), as evidenced by the US FDA approval of LNPs of small interfering RNA (siRNA) (Onpattro) (31) and mRNA-LNP COVID-19 vaccines (e.g., Comirnaty (32) and Spikevax (33)).”
Rzymski, P., Sikora, D., Zeyland, J., Poniedziałek, B., Kiedik, D., Falfushynska, H., & Fal, A. (2022) · Vaccines · doi:10.3390/vaccines10050754 · Cited by 12
Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
Azzi, L., Focosi, D., Dentali, F., Baj, A., & Maggi, F. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.086 · Cited by 11
Archaeal ether lipids improve internalization and transfection with mRNA lipid nanoparticles
Sedlmayr, V. L., Schobesberger, S., Spitz, S., Ertl, P., Wurm, D. J., Quehenberger, J., & Spadiut, O. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114213 · Cited by 13
Catch the tweet to fight the flu: Using Twitter to promote flu shots on a college campus
Osborne, M., Kenah, E., Lancaster, K. E., & Tien, J. H. (2021) · Journal of American College Health · doi:10.1080/07448481.2021.1973480 · Cited by 10
Kelsen, S. G., Braverman, A. S., Aksoy, M. O., Hayman, J. A., Patel, P. S., Rajput, C., Zhao, H., Fisher, S. G., Ruggieri, M. R., & Gentile, N. (2022) · JCI Insight · doi:10.1172/jci.insight.155889 · Cited by 13
“JCI Insight 2022;7(4):e155889 https://doi.”
Impact of BMI on COVID-19 vaccine effectiveness
Wilder‐Smith, A., & Frahsa, A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00170-x · Cited by 11
Karatas, E., Nazim, A., Patel, P., Vaidya, T. S., Drew, G. S., Amin, S. A., Jacobs, A. K., Fonseca, M., Mir, A., & Halverstam, C. P. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.12.002 · Cited by 11
“Clinical trials of both vaccines reported no safety concerns other than a few local and systemic reactions.(1,2) Overall, these reported reactionswere transient and resolvedwithin a couple of days.”
BackgroundPařenica, J., Benešová, K., Radvan, M., Sanca, O., Hlásenský, J., Lokaj, P., Ondrúš, T., Helánová, K., Kala, P., Dušek, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.998842 · Cited by 12
Enhancement of synthetic mRNA translation efficiency through engineered poly(A) tails
Liu, Y., Nie, H., Sun, R., Wang, J., & Lu, F. (2021) · doi:10.1101/2021.08.30.458298 · Cited by 11
Tiwari, A., Sharan, T. S., Sharma, S., & Sharma, N. (2022) · Cogent Engineering · doi:10.1080/23311916.2022.2105559 · Cited by 11
Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
Córdoba, K. M., Jericó, D., Sampedro, A., Jiang, L., Iraburu, M. J., Martini, P. G. V., Berraondo, P., Avila, M. A., & Fontanellas, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.005 · Cited by 14
Serological response to COVID-19 vaccination in IBD patients receiving biologicsPreprint
Wong, S.-Y., Dixon, R. E., Pazos, V. M., ICARUS-IBD Working Group, Gnjatic, S., Colombel, J., & Cadwell, K. (2021) · medRxiv · doi:10.1101/2021.03.17.21253848 · Cited by 11
Abdallah, A.-O. A., Mahmoudjafari, Z., Atieh, T., Ahmed, N., Cui, W., Shune, L. O., Mohan, M., McGuirk, J. P., Remker, C., Foss, M., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13826 · Cited by 11
“The efficacy of the BNT162b2 and mRNA-1273 against SARS CoV-2 in healthy adults has been clearly demonstrated.(3,4) A high but variable mortality (27%–57%) in SARS CoV-2 hospitalized patients with PCD was reported by the International Myeloma Society.”
BackgroundOnn, P., & Chang, C. L. (2021) · Respirology Case Reports · doi:10.1002/rcr2.860 · Cited by 11
“8% protection against COVID-19 in adults in phase III clinical trials.(1) It is administered intramuscularly in two doses, 30 mcg each, at 21 days apart.”
BackgroundYoon, S., Widyasari, K., Jang, J., Lee, S. J., Kang, T., & Kim, S. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08728-5 · Cited by 10
Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice
Mukesh, R. K., Hill, T., Kaiser, F. K., Prado-Smith, J., Schulz, J. E., Gallogly, S., Herbold, L., Bauer, K., Smith, B. J., Myers, L. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-06880-3 · Cited by 13
Meyer-Szary, J., Bazgier, M., Lubocka, P., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0152 · Cited by 11
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
Gentile, I., Maraolo, A. E., Buonomo, A. R., Nobile, M., Piscitelli, P., Miani, A., & Moriello, N. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111159 · Cited by 10
Branche, A. R., Mulligan, M. J., Maniar, A., Puente, O. A., Oladipupo, I., Crowther, G., Zareba, A., Yi, Z., Scully, I. L., Gomme, E. A., et al. (2025) · Vaccines · doi:10.3390/vaccines13040383 · Cited by 12
“Of note, two safe and efficacious lipid nanoparticle-encapsulated modRNA vaccines encoding the SARS-CoV-2 spike protein were developed and successfully deployed in response to the global public health emergency presented by the COVID-19 pandemic [14,15].”
Self-citationChida, K., Takahashi, T., Igarashi, S., Fujimoto, K., Ogasawara, Y., Fujiwara, S., Koji, T., Kubo, Y., & Ogasawara, K. (2022) · NMC Case Report Journal · doi:10.2176/jns-nmc.2022-0012 · Cited by 11
Park, J. K., Lee, E. B., & Winthrop, K. L. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225492 · Cited by 14
“37 48”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.